Anil J. Trindade

Anil J. Trindade

Auto-generated profile, based on publicly available information

Anil J. Trindade

Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2021 in Transplant Infectious Disease
Verified
Journal Article
Open access
PDF file
BSBonnie Ann Sarrell
Bonnie Ann Sarrell
KBKaren Bloch
Karen Bloch
ACAlissar El Chediak
Alissar El Chediak
KKKayla Kumm
Kayla Kumm
KTKaitlyn Tracy
Kaitlyn Tracy
BCBeatrice P. Concepcion
Beatrice P. Concepcion
Solid organ transplant (SOT) recipients are at high risk for severe coronavirus disease 2019 (COVID‐19). Studies suggest that early intervention with monoclonal antibody (MAB) treatment directed against the SARS‐CoV‐2 spike protein may reduce the risk of emergency department visits or hospitalization for COVID‐19, especially in high‐risk patients. Herein, we describe our single‐center experience of 93 SOT (50 kidney, 17 liver, 11 lung, nine heart, and six dual‐organ) recipients with mild to moderate COVID‐19 who were treated with bamlanivimab or casirivimab‐imdevimab per emergency use authorization guidelines. Median age of recipients was 55 [(Interquartile range) 44–63] years, and 41% were diabetic. Median time from transplant to MAB was 64 (IQR 24–122) months and median time from the onset of COVID‐19 symptoms to the infusion was 6 (IQR 4–7) days. All patients had a minimum 30 days of study follow‐up. The 30‐day hospitalization rate for COVID‐19‐directed therapy was 8.7%. Infusion‐related adverse events were rare and generally mild. Biopsy‐proven organ rejection occurred in two patients, and there were no graft losses or deaths. A comparator group of 72 SOT recipients diagnosed with COVID‐19 who were eligible but did not receive MAB treatment had a higher 30‐day hospitalization rate for COVID‐19‐directed therapy (15.3%), although this difference was not statistically significant, after adjustment for age (Odds Ratio 0.49 [95% Confidence Interval 0.18–1.32],p= 0.16). Our experience suggests that MAB treatment, with respect to the available MAB formulations and circulating viral variants present during our study period, may provide favorable outcomes for mild to moderate COVID‐19 in SOT recipients.

24 January 2023 in Transplant Infectious Disease
Verified
Journal Article
Closed access
JGJason D. Goldman
Jason D. Goldman
SPStephanie M. Pouch
Stephanie M. Pouch
AWAnn E. Woolley
Ann E. Woolley
SBSarah E. Booker
Sarah E. Booker
CJCourtney T. Jett
Courtney T. Jett
LDLara Danziger‐Isakov
Lara Danziger‐Isakov

16 November 2022 in Transplantation Direct
Verified
Journal Article
Open access
ATAnil J. Trindade
Anil J. Trindade
KCKaitlyn C. Agnp Chapin
Kaitlyn C. Agnp Chapin
AMAmy Mullican
Amy Mullican
JGJennifer N. Gray
Jennifer N. Gray
HHHaley Agnp Hoy
Haley Agnp Hoy
CSCiara M. Shaver
Ciara M. Shaver
Export Background. Donor-derived cell-free DNA (dd-cfDNA) is a useful biomarker for the diagnosis of acute allograft injury within the first 1 to 2 y after lung transplant, but its utility for diagnosing chronic lung allograft dysfunction (CLAD) has not yet been studied. Understanding baseline dd-cfDNA kinetics beyond the initial 2 y posttransplant is a necessary first step in determining the utility of dd-cfDNA as a CLAD biomarker. We seek to establish baseline dd-cfDNA% levels in clinically stable lung allograft recipients who are >2 y posttransplant. Methods. We performed a prospective, single-center, observational study to identify plasma dd-cfDNA levels in clinically stable lung allograft recipients >2 y posttransplant. Results. Fifty-one subjects were enrolled and ≥3 baseline dd-cfDNA measurements were acquired during a median of 252 d. The median baseline percent dd-cfDNA level in our cohort was 0.45% (interquartile range [IQR], 0.26–0.69). There were statistically significant differences in dd-cfDNA based on posttransplant duration (≤5 y posttransplant median 0.41% [IQR, 0.21–0.64] versus >5 y posttransplant median 0.50% [IQR, 0.33–0.76]; P < 0.02). However, the clinical significance of this small change in dd-cfDNA is uncertain because this magnitude of change is within the biologic test variation of 73%. Conclusions. This study is the first to define levels of dd-cfDNA in clinically stable patients who are >2 y post–lung transplant. These findings lay the groundwork for the study of dd-cfDNA as a possible biomarker for CLAD.

24 May 2023 in Transplantation Direct
Verified
Journal Article
Open access
ATAnil J. Trindade
Anil J. Trindade
KCKaitlyn C. Agnp-C Chapin
Kaitlyn C. Agnp-C Chapin
JGJennifer N. Gray
Jennifer N. Gray
YFYuka Md Furuya
Yuka Md Furuya
AMAmy Mullican
Amy Mullican
CSCiara M. Shaver
Ciara M. Shaver
Background.: Donor-derived cell-free DNA (dd-cfDNA%) is a biomarker of early acute lung allograft dysfunction (ALAD), with a value of ≥1.0% indicating injury. Whether dd-cfDNA% is a useful biomarker in patients >2 y posttransplant is unknown. Our group previously demonstrated that median dd-cfDNA% in lung recipients ≥2 y posttransplant without ALAD was 0.45%. In that cohort, biologic variability of dd-cfDNA% was estimated by a reference change value (RCV) of 73%, suggesting that change exceeding 73% may be pathologic. In this study, we aimed to determine whether dd-cfDNA% variability or absolute thresholds are optimal for detecting ALAD. Methods.: We prospectively measured plasma dd-cfDNA% every 3 to 4 mo in patients ≥2 y post–lung transplant. ALAD was defined as infection, acute cellular rejection, possible antibody-mediated rejection, or change in forced expiratory volume in 1 s >10%, and was adjudicated retrospectively. We analyzed area under the curve for RCV and absolute dd-cfDNA% and reported performance of RCV ≥73% versus absolute value >1% for discriminating ALAD. Results.: Seventy-one patients had ≥2 baseline measurements of dd-cfDNA%; 30 developed ALAD. RCV of dd-cfDNA% at ALAD had a greater area under the receiver operator characteristic curve than absolute dd-cfDNA% values (0.87 versus 0.69, P = 0.018). Test characteristics of RCV >73% for ALAD diagnosis were sensitivity 87%, specificity 78%, positive predictive value 74%, and negative predictive value 89%. In contrast, dd-cfDNA% ≥1% had sensitivity 50%, specificity 78%, positive predictive value 63%, and negative predictive value 68%. Conclusions.: Relative change in dd-cfDNA% has improved test characteristics for diagnosing ALAD compared with absolute values.

8 November 2022 in Transplant Infectious Disease
Verified
Journal Article
Open access
ATAnil J. Trindade
Anil J. Trindade
KCKaitlyn C. Chapin
Kaitlyn C. Chapin
WGWhitney D. Gannon
Whitney D. Gannon
HHHaley Hoy
Haley Hoy
CDCaitlin T. Demarest
Caitlin T. Demarest
CSCiara M. Shaver
Ciara M. Shaver
Background: Reports on outcomes following severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection in lung transplant recipients remain limited.Methods: We performed a single‐center, observational study of outcomes in lung transplant recipients diagnosed with SARS‐CoV‐2 between 5/1/2020 and 3/15/2022 that were followed for a median of 123 days. We analyzed changes in spirometry, acute lung allograft dysfunction (ALAD) incidence, hospitalization, mechanical ventilation needs, secondary infection, and survival.Results: In our cohort of 336 patients, 103 developed coronavirus disease (COVID) (27 pre‐Delta, 20 Delta, and 56 Omicron‐era). Twenty‐five patients (24%) required hospitalization and 10 patients ultimately died (10%). Among 85 survivors who completed ambulatory spirometry, COVID‐19 did not alter change in forced expiratory volume in 1 s (FEV1) or forced vital capacity (FVC) over time compared to the preceding 6 months. The pre‐COVID FEV1change was −0.05 ml/day (IQR −0.50 to 0.60) compared to −0.20 ml/day (IQR −1.40 to 0.70) post‐COVID (p = .16). The pre‐COVID change in FVC was 0.20 ml/day (IQR −0.60 to 0.70) compared to 0.05 ml/day (IQR −1.00 to 1.10) post‐COVID (p = .76). Although the cohort overall had stable lung function, 33 patients (39%) developed ALAD or accelerated chronic lung allograft dysfunction (FEV1decline >10% from pre‐COVID baseline). Nine patients (35%) with ALAD recovered lung function. Within 3 months of acute COVID infection, 18 patients (17%) developed secondary infections, the majority being bacterial pneumonia. Finally, vaccination with at least two doses of mRNA vaccine was not associated with improved outcomes.Conclusions: This study describes the natural history of SARS‐CoV‐2 infection in a large cohort of lung transplant recipients. Although one third of patients develop ALAD requiring augmented immunosuppression, infection with SARS‐CoV‐2 is not associated with worsening lung function. image

21 December 2022 in Transplantation
Verified
Journal Article
Open access
ATAnil J. Trindade
Anil J. Trindade
KCKaitlyn C. Msn Chapin
Kaitlyn C. Msn Chapin
WGWhitney D. Msn Gannon
Whitney D. Msn Gannon
DEDavid B. Erasmus
David B. Erasmus
CSCiara M. Shaver
Ciara M. Shaver
Export